Research
Hormonal
GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.
If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.
ModerateQualifiesLOW confidence
This study described a delayed time to peak concentration and modest reductions in peak drug levels while using GLP-1 RAs with certain oral medications, yet the total drug exposure remained typically unchanged.
Why this rating
Based on a systematic review of non-cancer oral medications; direct evidence for oral cancer drugs is lacking.
Source
The emerging implications of GLP-1 receptor agonists in radiation therapy
Trenton Reinicke et al. · The Oncologist · 2026
DOI 10.1093/oncolo/oyag073
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →